Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc3)
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Pollinex Quattro Ragweed (also known as Ragweed MATA MPL) is an ultra-short course subcutaneous immunotherapy developed by Allergy Therapeutics for the treatment of seasonal allergic rhinitis and conjunctivitis caused by ragweed pollen. The vaccine consists of a ragweed pollen extract that has been chemically modified with glutaraldehyde to create an allergoid, which reduces IgE-mediated reactivity while maintaining immunogenicity. This allergoid is adsorbed onto L-tyrosine and combined with the immunostimulatory adjuvant monophosphoryl lipid A (MPL). MPL acts as a Toll-like receptor 4 (TLR4) agonist, facilitating a shift from a Th2-mediated allergic response to a Th1-mediated protective response. The treatment is designed as a pre-seasonal course requiring only four injections, offering a more convenient dosing schedule than traditional allergy vaccines. It has completed Phase III clinical trials and is available in certain European markets on a named patient basis.
- Brand names
- Pollinex Quattro Ragweed
- Other names
- Ragweed MATA MPLModified Pollen Allergen Tyrosine Adsorbate + Monophosphoryl Lipid A
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc3).